A series of ring-constrained (N)-methanocarba-5′-uronamide 2,N 6 -disubstituted adenine nucleosides have been synthesized via Mitsunobu condensation of the nucleobase precursor with a pseudosugar ring containing a 5′-ester functionality. Following appropriate functionalization of the adenine ring, the ester group was converted to the 5′-N-methylamide. The compounds, mainly 2-chloro substituted derivatives, were tested in both binding and functional assays at human adenosine receptors (ARs), and many were found to be highly potent and selective A 3 AR agonists. Selected compounds were compared in binding to the rat A 3 AR to assess their viability for testing in rat disease models. The N 6 -(3-chlorobenzyl) and N 6 -(3-bromobenzyl) analogues displayed K i values at the human A 3 AR of 0.29 and 0.38 nM, respectively. Other subnanomolar affinities were observed for the following N 6 derivatives: 2,5-dichlorobenzyl, 5-iodo-2-methoxybenzyl, trans-2-phenyl-1-cyclopropyl, and 2,2-diphenylethyl. Selectivity for the human A 3 AR in comparison to the A 1 AR was (fold): the N 6 -(2,2-diphenylethyl) analogue 34 (1900), the N 6 -(2,5-dimethoxybenzyl) analogue 26 (1200), the N 6 -(2,5-dichlorobenzyl) and N 6 -(2-phenyl-1-cyclopropyl) analogues 20 and 33 (1000), and the N 6 -(3-substituted benzyl) analogues 17, 18, 28, and 29 (700-900). Typically, even greater selectivity ratios were obtained in comparison with the A 2A and A 2B ARs. The (N)-methanocarba-5′-uronamide analogues were full agonists at the A 3 AR, as indicated by the inhibition of forskolin-stimluated adenylate cyclase at a concentration of 10 µM. The N 6 -(2,2-diphenylethyl) derivative was an A 3 AR agonist in the (N)-methanocarba-5′-uronamide series, although it was an antagonist in the ribose series. Thus, many of the previously known groups that enhance A 3 AR affinity in the 9-riboside series, including those that reducing intrinsic efficacy, may be adapted to the (N)-methanocarba nucleoside series of full agonists.